Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc ASPEN-1 Phase 3 Results Conference Call Transcript

Oct 14, 2020 / 12:30PM GMT
Release Date Price: €22.4 (-3.45%)
Operator

Welcome to the Revance Therapeutics conference call to discuss top line results from its ASPEN-1 Phase III trial of DaxibotulinumtoxinA for Injection in cervical dystonia. (Operator Instructions) As a reminder, this conference is being recorded today, Wednesday, October 14, 2020.

I would now like to turn the conference over to Jeanie Herbert, Head of Investor Relations for Revance. Please go ahead.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Shannon. With me on today's call from Revance Therapeutics are President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; Chief Operating Officer, Aesthetics and Therapeutics, Dustin Sjuts; and Senior Vice President of Clinical Development, Dr. Roman Rubio.

This morning, Revance Therapeutics announced results from our ASPEN-1 Phase III trial of DaxibotulinumtoxinA for Injection in cervical dystonia. If you have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot